Patrick L Day1, Steven J Eckdahl2, Joseph J Maleszewski3, Thomas C Wright4, David L Murray5. 1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: day.patrick@mayo.edu. 2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: eckdahl.steven@mayo.edu. 3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: maleszewski.joseph@mayo.edu. 4. College of Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: tcarsonwright@gmail.com. 5. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: murray.david@mayo.edu.
Abstract
OBJECTIVE: Chromium, cobalt, and vanadium are used in metallic joint prosthesis. Case studies have associated elevated heart tissue cobalt concentrations with myocardial injury. To document the long term heart metal ion concentrations, a validated inductively coupled plasma mass spectroscopy (ICP-MS) method was needed. METHOD: The method utilized a closed-vessel microwave digestion system to digest the samples. An ICP-MS method utilizing Universal Cell Technology was used to determine our target analyte concentrations. Accuracy was verified using reference materials. Precision, sensitivity, recovery and linearity studies were performed. This method was used to establish a reference range for a non-implant containing cohort of 80 autopsy human heart tissues RESULTS: This method demonstrated an analytic measurement range of 0.5-100ng/mL for each element. Accuracy was within ±10% of target value for each element. Within-run precision for each element was below 20% CV. The chromium, vanadium and cobalt concentrations (mean±SD) were 0.1523±0.2157μg/g, 0.0094±0.0211μg/g and 0.1039±0.1305μg/g respectively in 80 non-implant containing human heart tissue samples. CONCLUSIONS: This method provides acceptable recovery of the chromium, cobalt and vanadium in heart tissue; allowing assessment of the effects of metallic joint prosthesis on myocardial health.
OBJECTIVE:Chromium, cobalt, and vanadium are used in metallic joint prosthesis. Case studies have associated elevated heart tissue cobalt concentrations with myocardial injury. To document the long term heart metal ion concentrations, a validated inductively coupled plasma mass spectroscopy (ICP-MS) method was needed. METHOD: The method utilized a closed-vessel microwave digestion system to digest the samples. An ICP-MS method utilizing Universal Cell Technology was used to determine our target analyte concentrations. Accuracy was verified using reference materials. Precision, sensitivity, recovery and linearity studies were performed. This method was used to establish a reference range for a non-implant containing cohort of 80 autopsy human heart tissues RESULTS: This method demonstrated an analytic measurement range of 0.5-100ng/mL for each element. Accuracy was within ±10% of target value for each element. Within-run precision for each element was below 20% CV. The chromium, vanadium and cobalt concentrations (mean±SD) were 0.1523±0.2157μg/g, 0.0094±0.0211μg/g and 0.1039±0.1305μg/g respectively in 80 non-implant containing human heart tissue samples. CONCLUSIONS: This method provides acceptable recovery of the chromium, cobalt and vanadium in heart tissue; allowing assessment of the effects of metallic joint prosthesis on myocardial health.
Authors: Cody C Wyles; Christopher R Paradise; Thao L Masters; Robin Patel; Andre J van Wijnen; Matthew P Abdel; Robert T Trousdale; Rafael J Sierra Journal: J Arthroplasty Date: 2019-11-27 Impact factor: 4.757